SCHEMBL6324006

SCHEMBL6324006

COc1ccc(-c2noc(N)c2C(=O)NCCc2ccccc2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 3/20 0.48
HTT P42858 2/20 0.48
TAAR1 Q96RJ0 1/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 1/20 0.47
HIF1A Q16665 2/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FAAH O00519 1/20 0.43
PKM P14618 1/20 0.43
KLF5 Q13887 1/20 0.43
CD274 Q9NZQ7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317605 0.94 L3MBTL1 (0.57) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6324304 0.93 L3MBTL1 (0.53) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL6317731 0.91 SMN1; SMN2 (0.51) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL6324039 0.90 ALDH1A1 (0.52) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL6316636 0.89 HIF1A (0.50) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL6323447 0.87 EPHX2 (0.45) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL6323876 0.85 CNR1 (0.46) MEN1KMT2AALDH1A1HTTHPGD
SCHEMBL6618320 0.85 RIPK1 (0.45) RAB9ALMNACD274
SCHEMBL6315289 0.85 RAB9A (0.46) MEN1KMT2AL3MBTL1HTTHPGD
SCHEMBL6316178 0.84 GABRA1 (0.47) L3MBTL1NPC1RAB9ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885MEN1 2789/4885KMT2A 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.